Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willing and able to provide written informed consent
Infection with HCV genotype 1
HCV RNA \> LLOQ at screening
Participation in a prior Gilead-sponsored study
Screening laboratory values within defined thresholds
Use of two effective contraception methods if female of childbearing potential or sexually active male
Must be of generally good health, with the exception of chronic HCV infection, as determined by the Investigator
Must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments
You may not be if
Pregnant or nursing female or male with pregnant female partner
Co-infection with HIV or hepatitis B virus (HBV)
Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only)
Hepatocellular carcinoma (HCC)
History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
Clareo Health | Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
